Answers are grounded in this paper and cite their sources.
This study examines the association of standard-of-care systemic lupus erythematosus (SLE) medications with key outcomes such as low disease activity attainment, flares, damage accrual, and steroid-sparing, for which there is current paucity of data.
No takes yet. Share an insight, caveat, or question.
Montes et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: